Vyome Holdings Inc. (NASDAQ: HIND) announced phase 2 clinical trial results for VT-1953, a topical gel designed to treat symptoms ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE